Latest News for: chugai

Edit

Other Items Provided Electronically for the Notice of Convocation of the 115th Annual General Meeting of Shareholders (Items Omitted from the Paper Copy) [PDF 441KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Feb 2026
Please note that the following purports to be a translation from the Japanese original Notice of Convocation of the 115th Annual General Meeting of Shareholders for the business term ended December 31, 2025 of Chugai Pharmaceutical Co., Ltd.
Edit

Business Report of the 115th Annual General Meeting of Shareholders [PDF 1.1MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Feb 2026
Please note that the following purports to be a translation from the Japanese original Notice of Convocation of the 115th Annual General Meeting of Shareholders for the Business Term Ended December 31, 2025 of Chugai Pharmaceutical Co., Ltd.
Edit

Notice of Convocation of the 115th Annual General Meeting of Shareholders [PDF 3.5MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Feb 2026
Please note that the following purports to be a translation from the Japanese original Notice of Convocation of the 115th Annual General Meeting of Shareholders for the Business Term Ended December 31, 2025 of Chugai Pharmaceutical Co., Ltd.
Edit

Chugai Launches “ELEVIDYS” as Japan’s First Regenerative Medical Product for Duchenne Muscular Dystrophy (Chugai Pharmaceutical Co Ltd)

Public Technologies 20 Feb 2026
Chugai Launches "ELEVIDYS" as Japan's First Regenerative Medical Product for Duchenne Muscular Dystrophy ... TOKYO, February 20, 2026 -- Chugai Pharmaceutical Co., Ltd ... Osamu Okuda, Chugai's President and CEO ... Chugai Pharmaceutical Co.
Edit

Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Autoimmune Hemolytic Anemia (Chugai Pharmaceutical Co Ltd)

Public Technologies 19 Feb 2026
Chugai Pharmaceutical Co., Ltd ... (website in Japanese only) and Chugai Pharmaceutical Co., Ltd ... Zenyaku and Chugai are committed to working closely together to ensure that Rituxan ... [email protected] Investor Relations Group ... [email protected].
Edit

Notice of the Establishment of a Subsidiary（156KB） (Chugai Mining Co Ltd)

Public Technologies 16 Feb 2026
). February 13, 2026 ... Chugai Mining Co., Ltd ... The Company announces the establishment of Chugai Hawaii LLC, which began operations in November 2025 ... 1 ... CHUGAI HAWAII LLC. 2 ... * In December 2025, we increased the capital of CHUGAI HAWAII LLC ... Chugai Mining Co.
Edit

NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period (Chugai Pharmaceutical Co Ltd)

Public Technologies 09 Feb 2026
NXT007 is a Chugai-originated compound currently under development for hemophilia A ... TOKYO, February 9, 2026 -- Chugai Pharmaceutical Co., Ltd ... Osamu Okuda, Chugai's President and CEO ... Chugai Pharmaceutical Co.
Edit

Supplementary Materials [PDF 665KB] Supplementary Materials [Excel 255KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 29 Jan 2026
Chugai shareholders ... Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results ... Chugai shareholders.
Edit

Full Year Results (Jan-Dec 2025) [PDF 1.2MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 29 Jan 2026
Chugai Pharmaceutical Co., Ltd ... 4519 (URL https.//www.chugai-pharm.co.jp/english) Representative ... Net income attributable to Chugai shareholders ... In preparing Chugai performance outlook, Chugai has assumed exchange rates of ¥184/CHF, ¥179/EUR,.
Edit

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026
Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer ... TOKYO, January 28, 2026 -- Chugai Pharmaceutical Co., Ltd ... Chugai Pharmaceutical Co.
Edit

Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026
Preclinical results of ROSE12, an anti-CTLA-4 switch antibody engineered with Chugai's proprietary Switch-Ig technology, have been accepted by the Journal for ImmunoTherapy of Cancer, a leading journal in cancer immunotherapy.
Edit

Presentation [PDF 714KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 15 Jan 2026
CHUGAI PHARMACEUTICAL CO., LTD ... This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd ... Chugai will not comment on undisclosed financial results ... Chugai products.
Edit

KRAS Inhibitors Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Pfizer, Roche, Chugai, ...

GetNews 08 Jan 2026
The Key KRAS Inhibitors Companies in the market include - Pfizer, Roche/Chugai/Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, and Astex Pharmaceuticals, ... Roche/Chugai/Genentech.
Edit

Corporate Governance Report [PDF 1MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Dec 2025
Please note that the following is an unofficial English translation of the Japanese original text of the Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD. (“Chugai” or the “Company”), which is reported to the Tokyo Stock Exchange.
Edit

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Chugai Pharmaceutical Co Ltd)

Public Technologies 18 Dec 2025
). December 18, 2025 ... Chugai Pharmaceutical Co., Ltd ... TOKYO, December 18, 2025 -- Chugai Pharmaceutical Co., Ltd ... Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights ... Chugai Pharmaceutical Co.

Article Search

tools
×
×
×
×